Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.
Lock-in expiries on $4 billion of newly listed Indian shares added pressure to a stock market already down $1 trillion since December. Weak sentiment and slowing earnings growth may impact upcoming ...